Market evolution: Blood products (CN 300290) — 2015–2025

Introduction

This report examines the evolution of the European Union's external trade in products classified under customs code 300290: "Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses". The analysis covers the period from 2015 to 2025, relying on annual trade data. The provided data reveals a period of profound transformation, marked by a general contraction in trade volumes and a significant shift in the EU's market position. The period is characterized by a dramatic collapse in both export and import values and quantities, leading to a substantial improvement in the EU's trade balance for these goods. This report interprets these dynamics through three main perspectives: the overarching trends in trade flow, the structural changes within the market, and the evolving volatility and vulnerability of supply chains.

1. The Great Contraction: A Collapse in Trade Flows and a Shift Toward Self-Sufficiency

The most striking feature of the 2015–2025 period is the severe contraction of the EU's trade in blood products with the rest of the world. Both exports and imports fell precipitously from their initial levels, though the decline was more pronounced on the export side.

1.1. A Synchronized Downturn in Exports and Imports

Between the first and last year of the data window, the EU's total exports of CN 300290 products fell by 93.4% in value and 87.2% in quantity. Similarly, imports declined by 81.2% in value and 89.1% in quantity. The peak year for trade was 2019, after which a sharp decline accelerated, likely influenced by the COVID-19 pandemic's disruption to global supply chains and clinical trials.

1.2. Dramatic Improvement in the Trade Balance and Reduced External Reliance

The asymmetric decline—where exports fell faster than imports—paradoxically led to a sharp deterioration of the trade balance in the early part of the period, reaching a deficit of over €1.15 billion in 2023. However, by 2025, the deficit had nearly closed, resulting in a near-balanced trade position. This shift is underpinned by a fundamental change in the EU's production and consumption dynamics.

Concurrently, the EU's net import reliance on third countries for these products fell from 69.7% in 2015 to 42.8% in 2025. This indicates a marked move toward greater self-sufficiency or reduced demand for external supply.

1.3. Price Dynamics: A Tale of Two Trajectories

Price trends diverged significantly between exports and imports. Export prices fell by 48.9% over the period, suggesting either a shift in the product mix towards lower-value goods or increased competitive pressure. In stark contrast, import prices surged by 71.2%. This sharp rise in import unit values points to tightening global supply, a shift to more specialized or costly product grades, or the passing-through of higher input costs by external suppliers.

2. Shifting Partnerships and Increased Market Fragmentation

The contraction in overall trade was accompanied by significant changes in the geographic concentration of trade partners and the internal specialization of EU member states.

2.1. Diversification of Trade Partners and Reduced Dominance of Traditional Allies

The concentration of trade, measured by the Herfindahl-Hirschman Index (HHI), decreased for both exports and imports. This indicates a move away from reliance on a few dominant partners. For instance, the United States, while still a major partner for both flows, saw its share of EU imports and exports collapse by over 84% and 97% respectively in value terms.

2.2. Internal EU Specialization: A Niche for Specific Member States

Within the EU, production is highly concentrated. In 2025, a few member states displayed a strong comparative advantage (RSCA) in this sector, notably Hungary (0.76), Ireland (0.64), and Belgium (0.56). Conversely, many member states, particularly in Eastern and Northern Europe, have minimal to no specialization, as reflected in negative RSCA values. This suggests the EU's trade in these products is driven by specialized production clusters rather than being evenly distributed.

2.3. The Asymmetric Role of EU Member States in Trade

When looking at which EU countries were most active in extra-EU trade, the data reveals a core group. For imports, Sweden, Ireland, and Germany were consistently the largest recipients. For exports, Ireland and Germany were the dominant shippers. However, all major EU exporters saw their shipment values fall dramatically over the decade, with Ireland's exports dropping by 99.2%.

3. Volatility, Price Shocks, and Evolving Supply Chain Risks

Despite the overall contraction, the period was not smooth. Significant price volatility and isolated supply shocks highlight underlying fragility in the market for these sensitive products.

3.1. High and Disparate Price Volatility Among Partners

Analysis of volatility (Coefficient of Variation) shows that trade with many partners was highly unstable. Import volatility was particularly acute with Argentina (CV: 1.64) and Norway (CV: 1.35). On the export side, flows to Belarus (CV: 1.91) and Thailand (CV: 1.47) were highly erratic. This points to fragile, opportunistic, or small-volume relationships rather than stable, long-term supply chains.

3.2. Notable Supply and Price Shocks

The data identifies specific shock events, predominantly on the export side. A major price shock occurred in 2022 for exports to Vietnam, with an abnormality score of 1188.2 and a price shift of +441.7%. Another significant price shock occurred in exports to Ecuador in 2023. These could reflect one-off contracts for specific high-value consignments, changes in product specifications, or payment term effects.

3.3. The Surge in Import Prices: A Signal of Tighter Markets

The 71.2% rise in average import prices is a critical risk indicator. It suggests that while the EU has reduced its volume of imports, the cost per unit of the imports it still requires has increased substantially. This could reflect a global seller's market for certain specialized blood-derived inputs, higher compliance costs, or a strategic shift by the EU to source more complex, higher-value preparations, thereby accepting higher unit costs for greater therapeutic or diagnostic utility.

Conclusion

Over the 2015–2025 decade, the EU's market for blood products (CN 300290) underwent a fundamental restructuring. It moved from a state of significant net import reliance and large-scale export activity to one of greatly reduced external engagement and near trade balance. This contraction was likely driven by a combination of internal EU policy developments, the catalytic effect of the COVID-19 pandemic in reshaping supply chains and clinical priorities, and a possible strategic pivot towards greater autonomy for critical medical products.

The market that remains is more geographically diversified but also more expensive, with import unit values rising sharply. Production is concentrated in a handful of specialized EU member states. While overall trade volatility decreased with shrinking volumes, sharp price shocks in specific bilateral relationships underscore the lingering risks in these sensitive and strategically important supply chains. The data points to a market that has become smaller, more inward-looking, and arguably more resilient, but also one facing new cost pressures.